Vertex Pharmaceuticals Incorporated – Biotechnology Stocks To Buy
Cystic Fibrosis is a disorder that significantly affects the lungs as well as the digestive system. The disorder affects the human body cells that produce mucus, digestive juices, and sweat. As you can imagine, these secretions are a vital part of a normally functioning human body. So, any disruption in these processes can have a serious impact on the overall health of a person. As a result, Cystic Fibrosis is a life-threatening condition. Studies suggest that the health condition is more common among people of North European ancestry. Cystic Fibrosis is not as common among people from Africa or Asia. Therefore, any medication or treatment for cystic fibrosis has a market in the Western world which normally consists of developed economies. One company, Vertex Pharmaceuticals, has made a set of medicines that treat Cystic Fibrosis. These medicines are very profitable. Vertex Pharmaceuticals is among the best biotechnology stocks now.
Vertex Pharmaceuticals – Tacking The Biggest Challenges
Vertex Pharmaceuticals was founded by a Harvard-trained chemist Joshua Bogner in 1989. Joshua had a job with pharma giant Merck. However, he left the company to establish Vertex Pharmaceuticals in a garage in Cambridge, MA. Joshua’s vision behind starting Vertex Pharmaceuticals was to tackle the biggest challenges in human health. With that philosophy in mind, the company today has a portfolio of products meant to treat Cystic Fibrosis, which is widely regarded as a devastating genetic disease. Developing the set of medicines meant to treat Cystic Fibrosis was not easy. It took a decade and a lot of money. However, the rewards were significant – $1.7 billion in sales. Vertex now holds perhaps the most lucrative set of medicines treating Cystic Fibrosis. If you are looking for biotechnology stocks to buy, then check out Vertex Pharmaceuticals.
Vertex Pharmaceuticals is always attracted by the possibility of coming out with an exciting new drug. The company sees moonshots as a science mission. Vertex Pharmaceuticals’ stock has been in a downtrend for the past 12 months, as measured on October 8th, 2021.